The Pathology and Laboratory Support Core is an effective nucleus that supports the various studies of the program project by providing routine and advanced technical preparations, including morphological analysis of cells, tissue and organ preparations. The core provides diagnostic light microscopic evaluation, epifluorescent microscopy of histological sections and immunohistochemical interpretation of human and murine prostatic tissue and prostate cancer bone metastases. In addition, technologically advanced expert assistance in a broad range of methods, including quantitative RT-PCR and tissue in-situ hybridization are available. Program project investigators utilizing animal necropsies also have access to sophisticated techniques, such as transmission electron microscopy and image analysis/morphometry. Facilities available include histology (special stains, frozen, paraffin- and plastic-embedded sections) and immunohistochemistry. A key advantage of the core is that it enables unified characterization and dissemination of a shared set of histologic standards. Key to the study of the tumor-bone-stromal interaction is the ability to isolate relatively pure samples of the tumor and the surrounding stroma. Particularly relevant to our program project is the ability to do so in the primary tumor as well as in bone specimens with metastasis.The pathology core will a) procure fresh prostatic tissue, including: primary tumor, tumor-related stroma, benign epithelium, metastatic bone specimens, and stroma unrelated to tumor from clinical specimens under direct morphologic visualization using laser capture microscopy for molecular analyses;b) serve as the morphology core, providing prostate cancer diagnostic expertise for both clinical specimens and animal models of prostate cancer, maintain frozen section and light microscopic facilities, histochemistry, immunohistochemistry and in situ hybridization microscopic support;and c) provide ample well-characterized, archived pathologic samples for screening of candidate molecules of potential mechanistic importance, validation of cell culture and animal model experimental data anddiscovery of novel biomarkers, including high throughput analysis - tissue microarray.

Public Health Relevance

Core C will continue to provide both diagnostic and molecular analysis of cell and tissue samples from human and animals. This will allow for more comprehensive quality testing with wider variety of advanced methods. Procedures are standardized and quality-controlled, leading to greater technical uniformity and allowing for direct comparisons between projects. Investigators will continue to have ready access to sophisticated techniques such as transmission electron microscopy and image analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA098912-10
Application #
8528356
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
10
Fiscal Year
2013
Total Cost
$257,026
Indirect Cost
$39,849
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Rohena-Rivera, Krizia; Bhowmick, Neil A (2018) Notch inhibitor screening reveals an unexpected HES1 heterodimer. J Biol Chem 293:8295-8296
Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2018) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat 28:562-574
Madhav, Anisha; Andres, Allen; Duong, Frank et al. (2018) Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 37:4385-4397
Jan, Yu Jen; Chen, Jie-Fu; Zhu, Yazhen et al. (2018) NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Adv Drug Deliv Rev 125:78-93
Grindel, Brian J; Martinez, Jerahme R; Tellman, Tristen V et al. (2018) Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells. Sci Rep 8:7262
Jimenez, Jose L; Tighiouart, Mourad; Gasparini, Mauro (2018) Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents. Biom J :
Martinez, Jerahme R; Grindel, Brian J; Hubka, Kelsea M et al. (2018) Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome. J Cell Biochem :
Nandana, Srinivas; Tripathi, Manisha; Duan, Peng et al. (2017) Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. Cancer Res 77:1331-1344
Diniz, Márcio Augusto; Quanlin-Li; Tighiouart, Mourad (2017) Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method. J Biom Biostat 8:
Jolly, Mohit Kumar; Boareto, Marcelo; Debeb, Bisrat G et al. (2017) Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer 3:21

Showing the most recent 10 out of 215 publications